title: Predictors of post-operative response to treatment: a double blind placebo controlled study in chronic rhinosinusitis patients.
abstract: BACKGROUND
  In the majority of CRS patients suffering from primary or recurrent CRS, topical glucocorticoids are highly effective. A subset of CRS patients, however, does not respond to (topical) glucocorticoids and requires surgical intervention. Although surgery is highly effective in those individuals, recurrence of disease is observed in some. In this study we describe our search for one or more predictors predicting the response to surgery in combination with peri-operative oral glucocorticoids in CRS patients.
  
  
  METHODS
  Thirty-five inferior turbinate specimens were randomly selected from a larger group of CRS patients requiring FESS for persistent disease that either responded favorably or demonstrated recurrent disease. Tissue biopsies were taken at the time of surgery and compared for inflammatory markers, endothelial cell markers, and various leukocyte subsets using immunohistochemistry.
  
  
  RESULTS
  Compared to non-responders, the baseline level of lamina propria activated eosinophils is significantly increased in CRS patients responding to surgery in combination with peri-operative oral glucocorticoids treated or not treated post-operatively with topical glucocorticoids. No significant differences were observed for all other studied parameters. Post-operative treatment with FPANS 100 μg q.i.d. was significantly associated with response to treatment. A trend towards association was observed for increased numbers of eosinophils at baseline.
  
  
  CONCLUSIONS
  Our data suggest that CRS patients with higher levels of eosinophils are less likely to suffer from post-operative recurrent sinonasal disease when treated post-operatively with FPANS 100 μg q.i.d.
authors: Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, the Netherlands. f.a.ebbens@amc.uva.nl
authors: F A
authors: FA
authors: Ebbens
authors: S
authors: S
authors: Toppila-Salmi
authors: E J J
authors: EJ
authors: de Groot
authors: J
authors: J
authors: Renkonen
authors: R
authors: R
authors: Renkonen
authors: C M
authors: CM
authors: van Drunen
authors: M G W
authors: MG
authors: Dijkgraaf
authors: W J
authors: WJ
authors: Fokkens
mesh_terms: D000328:Adult; D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D004724:Endoscopy; D004804:Eosinophils / Q000378:metabolism; D005260:Female; D000068298:Fluticasone; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000378:metabolism; D059085:Nasal Sprays; D012008:Recurrence; D012220:Rhinitis / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D012852:Sinusitis / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D059085:Nasal Sprays; D000068298:Fluticasone